What is DermTech?
DermTech, Inc. operates as a molecular diagnostics firm focused on creating and commercializing innovative non-invasive genomics tests. These tests are designed to assist in the diagnosis and ongoing management of melanoma, a critical area within dermatological care. The company's approach aims to provide more accurate and less invasive diagnostic solutions, potentially transforming how melanoma is detected and monitored in the United States.
How much funding has DermTech raised?
DermTech has raised a total of $87.4M across 4 funding rounds:
Other Financing Round
$10M
Other Financing Round
$2.4M
Series C
$10M
Share Placement
$65M
Other Financing Round (2007): $10M with participation from Gary Jacobs and Gene Salkind
Other Financing Round (2015): $2.4M led by Undisclosed
Series C (2017): $10M supported by RTW Investments
Share Placement (2020): $65M featuring Undisclosed
Key Investors in DermTech
RTW Investments
RTW Investments is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle. The firm partners with companies at various stages of development, providing not just capital but also expertise to support their success.
What's next for DermTech?
With the recent major strategic investment and a substantial total funding history of $87.4M, DermTech is positioned for accelerated growth and market expansion. The company's focus on non-invasive genomics for melanoma diagnosis suggests a strategic move towards precision medicine within the diagnostics sector. Future developments are likely to involve scaling its commercial operations, further research and development into its genomic testing platforms, and potentially expanding its diagnostic applications beyond melanoma, leveraging its established technological foundation and investor backing.
See full DermTech company page
